Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the
prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications
and particularly Graft versus Host Disease (GvHD).
The hypothesis of this study is that allogeneic FMT may improve outcomes of these patients.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Clermont-Ferrand
Collaborators:
French Society of Hematology Ministry of Health, France